Slide 1: Q2 2026 Financial Results
Q2 2026 Financial Results July 28, 2026 Nasdaq: NEO
Slide 2: Safe Harbor Statements
Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. (“we,” ”us,” “our,” “NeoGenomics” or the “Company”). Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation includes forward-looking statements. These forward-
Slide 3: Mission and Vision
Mission We take cancer personally. We partner with physicians to deliver actionable insights that guide personalized treatment decisions and improve outcomes – through a comprehensive oncology portfolio, integrated customer solutions, and an unwavering commitment to excellence. Vision A world where
Slide 4: NEO: Investment Thesis
NEO: Investment Thesis Positioned to lead in precision oncology $20B+ MRD market entry Pure-play oncology solutions provider RaDaR ST launch opens a fast-growing solid-tumor MRD Focused commercial engine drives rapid adoption segment Hematology leadership Partner of choice Lab consolidation drives t
Slide 5: One Provider from Diagnosis to Recurrence Monitoring
One Provider from Diagnosis to Recurrence Monitoring MRD Diagnostic Testing Therapy Selection Recurrence Monitoring $12B | 7% CAGR $13B | 13-15% CAGR $20B | 30% CAGR Penetration: 70% 35% <8% Flagship products: Sources: SEER, NCCN, NHS, NSF, NIH, UN, WHO, Precedence Research, primary market research,
Slide 6: Strong Revenue and Adjusted EBITDA Growth
Strong Revenue and Adjusted EBITDA Growth Revenue ($M) Adj EBITDA ($M) $14M $202M $181M $11M 11% 36% YoY YoY growth growth Q2 2025 Q2 2026 Q2 2025 Q2 2026 Quarterly financial information is unaudited. Growth corresponds to prior year period. Adjusted EBITDA is a non-GAAP financial measure. See Adjus
Slide 7: Clinical Performance Drives Growth
Clinical Performance Drives Growth Clinical Revenue Revenue per Test Volume (tests) $187M $515 363k 361k $174M $172M $171M $495 357k 356k $164M $488 $476 12% YoY Growth 14% YoY Growth 346k $461 2% YoY Growth Q2 Q3 Q4 Q1 Q2 Q2 Q3 Q4 Q1 Q2 Q2 Q3 Q4 Q1 Q2 2025 2025 2025 2026 2026 2025 2025 2025 2026 20
Slide 8: NGS is the Performance Catalyst
NGS is the Performance Catalyst +26% NGS Revenue +14% NGS Volume NGS Revenue Expect mid-twenties YoY revenue growth in 2026 Expect mid-teens YoY volume growth in 2026 ~1/3 of Clinical Revenue 26% 14% NGS Volume ~10% of Clinical Volume in Q2 Large NGS Panel >20% Volume Growth Q2 Q3 Q4 Q1 Q2 Q2 Q3 Q4
Slide 9: Winning in the Community Setting
Winning in the Community Setting ~80% of cancer patients are treated in the community — where NeoGenomics is focused GUIDELINE DRIVEN PORTFOLIO MARKET LEADERSHIP1 SERVICE EXCELLENCE2 500+ tests >25% NPS 78 Covering Diagnostic, Therapy Selection & Heme market share Heme NGS published TAT reduction MR
Slide 10: RaDaR ST: A Strategic Growth Engine in MRD
RaDaR® ST: A Strategic Growth Engine in MRD Tapping into the large, nascent, and rapidly growing MRD market for cancer recurrence monitoring TOTAL ADDRESSABLE MARKET COVERAGE1 HPV- Head & Neck Access to Subset of Breast >40% of MRD TAM 3 Pending Submissions ~30% ~2/3 ~1/3 Early Launch Insights – Exp
Slide 11: Sharpening our Commercial Focus
Sharpening our Commercial Focus Reorganized commercial team focused on Pathology and Oncology 160+ targeted commercial representatives — on track to grow by Q3 2026 Building the Oncology Sales Specialist team ahead of additional RaDaR ST reimbursement approvals Pathology Oncology Dedicated ecosystem
Slide 12: Lab of the Future – Modernizing our Infrastructure
Lab of the Future – Modernizing our Infrastructure Six integrated initiatives to drive gross margin expansion 03 01 02 Instrument Digital pathology Automation & AI Whole-slide imaging and Automated processing and platform upgrades digital diagnostic workflows AI-assisted analysis Next-generation seq
Slide 13: Adjusted Gross Margin Expanded 260bps in Q2
Adjusted Gross Margin Expanded 260bps in Q2 We expect 100-150bps of adjusted GM expansion for full year 2026 Adj Gross Margin FY Outlook 48% Q2 Gross Margin +260% +100-150bps ~260 bps AUP + Lab of the Future 46% 46% 46% 45% 45% FY Outlook ~100-150 bps Robust Margin Expansion Q2 Q3 Q4 Q1 Q2 FY FY 202
Slide 14: Operating Expenses, Margins, and Cash Position
Operating Expenses, Margins, and Cash Position OPERATING EXPENSE ADJ. EBITDA ADJ. EBITDA M ARGIN TOTAL CASH $102M $14M 7.2% $146M (3%) YoY* +36% YoY +130 bps YoY Period-end O P E R AT I N G L E V E R AG E C AS H P O S I T I O N • OpEx down (3%) YoY* to $102M, investments to Sales • Generated $20M of
Slide 15: Updating Full Year 2026 Guidance
Updating Full Year 2026 Guidance Guidance as of July 28, 2026 April 28, 2026 ($ Millions) YoY% Growth Assumptions Guide ($ Millions) YoY% Growth • Clinical revenue to grow low-teens % • NGS to grow mid-twenties % Revenue $797–803 10% $802–806 ~11% • PanTracer LBx revenue in MSD millions at midpoint
Slide 16: Growth Catalysts 2026+
Growth Catalysts 2026+ PROGRESS THROUGH Q2 | 3 GOALS ACHIEVED | 2 REMAIN ON TRACK 1 RaDaR ST launch — HPV- Head & Neck, Breast subset Achieved 2 PanTracer LBx MolDx reimbursement Achieved 3 Expanded indication reimbursement for RaDaR ST On Track 4 Above market NGS growth Achieved 5 Sales force expan
Slide 17: All rights reserved.
© 2026 NeoGenomics Laboratories, Inc. All rights reserved. All other trademarks are the property of their respective owners. Rev. 02.17.2026
Slide 18: Appendix
GENOMICS Appendix
Slide 19: Balance Sheet
Balance Sheet June 30, 2026 (unaudited, in thousands)
Slide 20: Income Statement
Income Statement June 30, 2026 (unaudited, in thousands)
Slide 21: Statements of Cash Flows
Statements of Cash Flows June 30, 2026 (unaudited, in thousands)
Slide 22: Adjusted Gross Margin
Adjusted Gross Margin June 30, 2026 (unaudited, in thousands) _________________ (1) Cost of revenue adjustments for the three months ended June 30, 2026, include $4.6 million of amortization of acquired intangible assets and $0.4 million of stock- based compensation. Cost of revenue adjustments for
Slide 23: Adjusted EBITDA
Adjusted EBITDA June 30, 2026 (unaudited, in thousands) _________________ (1) For the three and six months ended June 30, 2026, leadership transition costs include executive retention costs. For the three months ended June 30, 2025, leadership transition costs include executive retention costs. For
Slide 24: Adjusted EBITDA 2026 Guidance
Adjusted EBITDA 2026 Guidance (unaudited, in thousands) GAAP net loss in 2026 will be impacted by certain charges, including: (i) amortization, (ii) stock-based compensation, and (iii) other one-time expenses. These charges have been included in GAAP net loss available to stockholders and GAAP net l